[1] 刘燕, 刘晓辉, 宋艳玲, 等. 急性脑梗死患者血清Ⅰ型胶原羧基末端肽改变及其与颈动脉粥样硬化斑块的关系[J].心肺血管病杂志, 2018, 37(1):39-45. [2] 马玉梅, 霍清萍.基质金属蛋白酶9与动脉粥样硬化及中医药防治[J].中西医结合心脑血管病杂志, 2014, 12(9):1127-1128. [3] 郑辉, 刘慧娟, 葛焕琦, 等.网膜素改善氧化应激对人动脉血管平滑肌细胞Ⅰ、Ⅳ型胶原表达的抑制作用[J].中国动脉硬化杂志, 2016, 24(2):141-144. [4] DUNÉR P, GONÇALVES I, GRUFMAN H, et al.Increased aldehyde-modification of collagen type Ⅳ in symptomatic plaques:A possible cause of endothelial dysfunction[J].Atherosclerosis, 2015, 240(1):26-32. [5] MCLEOD O, DUNÉR P, SAMNEGÅRD A, et al.Autoantibodies against basement membrane collagen type Ⅳ are associated with myocardial infarction[J].Int J Cardiol Heart Vasc, 2015, 6(1):42-47. [6] ZHAO J, ZHANG S F, SHI Y, et al.Effects of urotensin Ⅱ and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J].Bosn J Basic Med Sci, 2013, 13(2):78-83. [7] BARKAREV M A, KARPOVA A A, PICHIGIN V I, et al.Involvement of the coronary bed in patients with coronary heart disease against the background of primarily coronary and generalized atherosclerosis[J].Bull Exp Biol Med, 2016, 162(2):283-287. [8] 赵娟, 宋成军, 姜菊花, 等.urantide对实验性动脉粥样硬化大鼠肝脏的影响[J].中国老年学杂志, 2014, 34(4):940-942. [9] ZHAO J, YU QX, KONG W, et al.The urotensin Ⅱ receptor antagonist, urantide, protects against atherosclerosis in rats[J].Exp Ther Med, 2013, 5(6):1765-1769. [10] KONDO T, ENDO I, AIHARA K, et al.Serum carboxy-terminal telopeptide of type Ⅰ collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors[J].Endocr J, 2016, 63(4):397-404. [11] CHUNG E J.Targeting and therapeutic peptides in nanomedicine for atherosclerosis[J].Exp Biol Med (Maywood), 2016, 241(9):891-898. [12] 田祥全, 万小松, 杨纪才, 等.血清Ⅰ型胶原羧基末端肽、基质金属蛋白-2水平与冠状动脉病变的关系[J].中国循证心血管医学杂志, 2016, 8(5):553-555. [13] 刘娜, 资晓宏.胶原在动脉粥样硬化斑块中的作用研究进展[J].浙江临床医学, 2017, 19(2):377-379. [14] 赵娟.Urantide抑制动脉粥样硬化大鼠单核细胞趋化蛋白-1的表达[J].中国药理学与毒理学杂志, 2011, 25(5):425-429. [15] 赵娟, 谢利德, 王红伟, 等.Urantide对实验性动脉粥样硬化大鼠白细胞介素-6表达的影响[J].中国老年学杂志, 2013, 33(8):1823-1824. [16] ZHAO J, XIE L D, SONG C J, et al.Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1and transforming growth factor-Urantide improves atherosclerosis by controlling C reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats[J].Exp Therapeut Med, 2014, 7(10):1647-1652. [17] ALBANESE I, DASKALOPOULOU S S, YU B, et al.The urotensin Ⅱ system and carotid atherosclerosis:A role in vascular calcification[J].Front Pharmacol, 2016, 7:149-157. [18] OH K S, LEE J H, YI K Y, et al.A novel urotensin Ⅱ receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure[J].Eur J Pharmacol, 2017, 799:94-102. [19] CHOW W Y, BIHAN D, FORMAN C J, et al.Hydroxyproline ring pucker causes frustration of helix parameters in the collagen triple helix[J].Sci Rep, 2015,5:12556. [20] 钱进, 邓辰亮, 杨松林, 等.建立SCID鼠增生性瘢痕模型的实验研究[J].组织工程与重建外科杂志, 2018, 14(1):31-35. |